What was your fracture risk evaluated by FRAX® the day before your osteoporotic fracture?

Clinical Rheumatology

Volumn 32, Issue 2, 2013, Pages 219-223

  Aubry Rozier, Bérengère ^a   Stoll, Delphine ^a   Krieg, Marc Antoine ^a   Lamy, Olivier ^a   Hans, Didier ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Fracture risk; FRAX ; FRAX Swiss thresholds; Osteoporosis

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; BONE DENSITY; COMPARATIVE STUDY; FEMALE; FOREARM FRACTURE; FRAGILITY FRACTURE; GROUPS BY AGE; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PELVIS FRACTURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 84878480017     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-2106-1     Document Type: Article

References (19)

1. Lippuner K, Golder M, Greiner R (2005) Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int 16:S8-S17
2. Suhm N, Lamy O, Lippuner K (1999) Management of fragility fractures in Switzerland: results of a nationwide survey. Swiss Med Wkly 138:674-683
3. Lippuner K, Johansson H, Kanis JA, Rizzoli R (2010) FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21:381-389
4. Krieg MA, Cornuz J, Ruffieux C et al (2006) Prediction of hip fracture risk by quantitative ultrasound in more than 7,000 Swiss women > or = 70 years of age: comparison of three technologically different bone ultrasound devices in the SEMOF study. J Bone Miner Res 21:1457-1463
5. Kanis JA, Borgstrom F, De Laet C et al (2005) Assessment of fracture risk. Osteoporos Int 16:581-589
6. Lippuner K, Johansson H, Kanis JA, Rizzoli R (2009) Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int 20:1131-1140
7. Aubry-Rozier B, Stoll D, Hans D, So A, Krieg MA, Lamy O (2010) Increasing treatment from 19 to 67 % 1 year after an osteoporotic fracture with an active pathway. Proc Meeting of the Swiss Society of Rheumatology, Fribourg, Switzerland, 2010, Swiss medical weekly p 23
8. Aubry-Rozier B, Stoll D, Hans D, Lamy O, Krieg MA (2010) What was your FRAX the day before your hip fracture? Proc Meeting of ECCEO, Firenze, Italia, 2010, Osteoporos Int S72
9. Kanis J, McCloskey EV, Johansson H, Oden A, Ström O, Borgström F (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21:S407-S413
10. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2009) How to decide who to treat. Best Pract Res Clin Rheumatol 23:711-726
11. Johansson H, Kanis JA, McCloskey EV et al (2011) A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporos Int 22:453-461
12. Borgstrom F, Ström O, Coelho J, Johansson H, Oden A, McCloskey E, Kanis JA (2010) The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int 21:339-349
13. Borgstrom F, Ström O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495-505
14. Fraser LA, Langsetmo L, Berger C et al (2011) Fracture prediction and calibration of a Canadian FRAX(R) tool: a population-based report from CaMos. Osteoporos Int 22:829-837
15. Sornay-Rendu E, Munoz F, Delmas PD, Chapurlat RD (2010) The FRAX tool in French women: how well does it describe the real incidence of fracture in the OFELY cohort? J Bone Miner Res 25:2101-2107
16. Briot K et al (2010) Validity of FRAX to predict major osteoporotic fracture: data of the OPUS cohort. Proc Meeting of the French Society of Rheumatology, Paris, France, 2010, Joint bone spine p A43
17. Kanis JA, Oden A, Johansson H, McCloskey E (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23:423-431
18. Roux C, Thomas T (2009) Optimal use of FRAX. Joint Bone Spine 76:1-3
19. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2011) Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 22:839-847